Trial Profile
Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms NATURE
- 22 Jun 2016 Planned End Date changed from 1 Apr 2019 to 1 May 2019.
- 22 Jun 2016 Status changed from recruiting to withdrawn prior to enrolment due to loss of funding support.
- 04 Apr 2016 New trial record